The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.
Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.
Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.
Okie, let’s look at the market. As I am very busy recently, my post is a lot slower. But, I am still monitoring the market closely. Today, the posts will be long, and the contents are as below: i) Current market-$SPDR 標普500指數ETF(SPY.US)$ ii) Oil price iii) My trade based on stage analysis i) To be honest, after the last month CPI showed that the inflation is still not under controlled, the big sell off volume ha...
Kiniksa Pharmaceuticals股票討論區
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
目前市盈率TTM 7.2,如果刨除所得稅返還影響,市盈率TTM其實還是負的。
由於只有一個季度的盈利數據,無法判斷持續盈利能力,繼續觀察。
Market analysis- 09Oct2022
i) Current market- $SPDR 標普500指數ETF(SPY.US)$
ii) Oil price
iii) My trade based on stage analysis
i) To be honest, after the last month CPI showed that the inflation is still not under controlled, the big sell off volume ha...
Watch this one Today and last hour of close !!!!
暫無評論